Imjudo (tremelimumab) is an anti-CTLA-4 agent. The approved regimen contains a fixed number (5) Imjudo cycles rather than Imjudo dosing until progression or discontinuation as is done with the Imfinzi/chemo portion of the regimen. The fixed-cycle dosing of Imjudo is intended to reduce the cumulative toxicity of the approved regimen. The approval is based on a statsig OS benefit in the triple combination arm of the POSEIDON trial compared to the chemo-only arm (https://www.clinicaltrials.gov/ct2/show/NCT031646).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.